Gsa Capital Partners LLP Zynerba Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.87 - $1.36 $1,191 - $1,861	-1,369 Reduced 1.03%	131,036 $96,000
Q2 2022 Aug 09, 2022	SELL	$0.86 - $2.06 $15,917 - $38,128	-18,509 Reduced 12.26%	132,405 $151,000
Q1 2022 May 11, 2022	SELL	$1.83 - $3.02 $219,340 - $361,971	-119,858 Reduced 44.27%	150,914 $309,000
Q4 2021 Feb 14, 2022	BUY	$2.88 - $4.3 $682,513 - $1.02 Million	236,984 Added 701.39%	270,772 $780,000
Q3 2021 Nov 12, 2021	BUY	$3.72 - $5.35 $125,691 - $180,765	33,788 New	33,788 $143,000
Q1 2020 May 12, 2020	SELL	$2.9 - $6.16 $64,107 - $136,172	-22,106 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$5.61 - $8.57 $124,014 - $189,448	22,106 New	22,106 $134,000
Q4 2018 Feb 12, 2019	SELL	$2.89 - $7.91 $62,713 - $171,647	-21,700 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$5.59 - $10.45 $121,303 - $226,764	21,700 New	21,700 $177,000
Q1 2018 May 11, 2018	SELL	$8.49 - $13.46 $329,412 - $522,248	-38,800 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$8.69 - $14.59 $337,172 - $566,092	38,800	38,800 $486,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.